John Mulligan, Ph.D.
Seattle, Washington, United States
2K followers
500+ connections
About
My scientific expertise is in drug discovery, genetics, and molecular biology. I was an…
Activity
-
John Crowley, the new CEO of BIO, is advocating a short-sighted, transactional approach to the Biosecure Act. His support for this effort risks…
John Crowley, the new CEO of BIO, is advocating a short-sighted, transactional approach to the Biosecure Act. His support for this effort risks…
Posted by John Mulligan, Ph.D.
-
The best 16 seconds of video that you’ll watch today…… courtesy of onboard Starlink. Starship reentry!
The best 16 seconds of video that you’ll watch today…… courtesy of onboard Starlink. Starship reentry!
Liked by John Mulligan, Ph.D.
-
Spotted in the wilds of Puget Sound last weekend: Chief Scientific Officer Diane Hollenbaugh repping the vast oncology research community and the…
Spotted in the wilds of Puget Sound last weekend: Chief Scientific Officer Diane Hollenbaugh repping the vast oncology research community and the…
Liked by John Mulligan, Ph.D.
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Stanford University
-
Research on the regulation of Rhizobium meliloti nodulation genes under the direction of Dr. Sharon Long.
-
-
Bacterial genetics research. Carried out what was probably the last experiment on glutamine synthetase auto-regulation for Boris Magasanik. Genetic analysis of the regulation of methionine biosynthetic genes in Graham Walker's lab led to a co-first author paper.
Publications
-
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
Am J Hum Genet. 2001 Mar;68(3):577-89
See publicationUsed human genetics to discover a target for drug development.
Patents
-
Antibodies associated with alterations in bone density
Issued US 7,758,858
Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF-.beta. binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.
Other inventors -
-
Automated polymer-synthesis system
Filed US 20110256031
Embodiments of the present invention are directed to automated-polymer-synthesis systems that include discrete reagent-solution-addition, wait-time, and reagent-solution-draining sub-systems which together significantly increase throughput and decrease sub-system idle time. The automated-polymer-synthesis systems that represent embodiments of the present invention additionally include switches at points in which carriers can be received from multiple input paths or output to multiple different…
Embodiments of the present invention are directed to automated-polymer-synthesis systems that include discrete reagent-solution-addition, wait-time, and reagent-solution-draining sub-systems which together significantly increase throughput and decrease sub-system idle time. The automated-polymer-synthesis systems that represent embodiments of the present invention additionally include switches at points in which carriers can be received from multiple input paths or output to multiple different output paths. The automated-polymer-synthesis systems that represent embodiments of the present invention generally include an input spur and output spur in addition to a main loop, allowing carriers containing only completed polymers to be removed and new carriers input, so that carriers traverse the automated-polymer-synthesis systems independently from one another.
Other inventors -
-
Wicking-based reagent-solution draining in an automated system
Filed US 20110236270
Embodiments of the present invention include processing steps and subsystems, within automated-biopolymer-synthesis systems and within other automated systems for organic-chemistry-based processing, for removing reagent solutions and solvents from reaction chambers following various synthetic reaction steps and washing steps undertaken during biopolymer synthesis. Embodiments of the present invention employ any of various different types of liquid-absorbing materials to wick, or remove by…
Embodiments of the present invention include processing steps and subsystems, within automated-biopolymer-synthesis systems and within other automated systems for organic-chemistry-based processing, for removing reagent solutions and solvents from reaction chambers following various synthetic reaction steps and washing steps undertaken during biopolymer synthesis. Embodiments of the present invention employ any of various different types of liquid-absorbing materials to wick, or remove by capillary action, liquids from reaction chambers. Wicking-based methods and subcomponents of the present invention remove significantly greater fractions of solutions from reaction chambers than conventional methods and subsystems and, in addition, are mechanically simpler and produce fewer deleterious side effects than currently used methods and subsystems.
Other inventors -
More activity by John
-
I am looking forward to chatting about our lead program and the cool technology it is based on.
I am looking forward to chatting about our lead program and the cool technology it is based on.
Shared by John Mulligan, Ph.D.
-
Spread the word: Gordian Biotechnology seeks a leader of teams spanning molecules and sequencing data, to take over the application and development…
Spread the word: Gordian Biotechnology seeks a leader of teams spanning molecules and sequencing data, to take over the application and development…
Liked by John Mulligan, Ph.D.
-
A common misconception among founders is that a large team means a healthy startup. Investors who have never built a company themselves often…
A common misconception among founders is that a large team means a healthy startup. Investors who have never built a company themselves often…
Liked by John Mulligan, Ph.D.
-
“Culture eats strategy for breakfast.” - Peter Drucker There are rare leaders such as Jobs, Gates, and Elon whose talent is so rare, their vision…
“Culture eats strategy for breakfast.” - Peter Drucker There are rare leaders such as Jobs, Gates, and Elon whose talent is so rare, their vision…
Liked by John Mulligan, Ph.D.
-
Please share: A new opportunity to work directly with me at Gordian Biotechnology as our Scientific Chief of Staff. You'd be at my side for…
Please share: A new opportunity to work directly with me at Gordian Biotechnology as our Scientific Chief of Staff. You'd be at my side for…
Liked by John Mulligan, Ph.D.
-
I am so proud to be working with these brilliant founders and the incredible team at Parse! We are transforming the future of single cell sequencing,…
I am so proud to be working with these brilliant founders and the incredible team at Parse! We are transforming the future of single cell sequencing,…
Liked by John Mulligan, Ph.D.
-
Bonum Therapeutics would like to thank all who contributed to our successes in 2023. We look forward to exciting things to come in 2024!
Bonum Therapeutics would like to thank all who contributed to our successes in 2023. We look forward to exciting things to come in 2024!
Liked by John Mulligan, Ph.D.
-
This morning we announced our new therapeutics company Ability Biologics. Thanks to everyone who has congratulated us and shared the news. As many…
This morning we announced our new therapeutics company Ability Biologics. Thanks to everyone who has congratulated us and shared the news. As many…
Liked by John Mulligan, Ph.D.
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More